Medicare proposes coverage limits for anti-anemia drugs

Medicare has proposed new restrictions on what it will cover for cancer patients prescribed anti-anemia drugs known as erythropoiesis-stimulating agents because of ties to death risks. Amgen makes Aranesp and Epogen and Johnson & Johnson makes Procrit for treating the problem, and they are expected to suffer the hardest hit if the Medicare proposal becomes final.

View Full Article in:

CNNMoney · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY